Valneva Past Earnings Performance
Past criteria checks 0/6
Valneva's earnings have been declining at an average annual rate of -31.3%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 26.8% per year.
Key information
-31.3%
Earnings growth rate
-26.1%
EPS growth rate
| Biotechs Industry Growth | 30.8% |
| Revenue growth rate | 26.8% |
| Return on equity | -79.1% |
| Net Margin | -66.0% |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Apr 05
Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)
Mar 27Is Valneva (EPA:VLA) Weighed On By Its Debt Load?
Mar 15News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts
Jan 06Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?
Dec 13Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?
Aug 10Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry
May 12Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt
Jan 30Is Valneva (EPA:VLA) Using Debt Sensibly?
Sep 18Industry Analysts Just Upgraded Their Valneva SE (EPA:VLA) Revenue Forecasts By 55%
Aug 13Party Time: Brokers Just Made Major Increases To Their Valneva SE (EPA:VLA) Earnings Forecasts
Jul 28Revenue & Expenses BreakdownBeta
How Valneva makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 154 | -101 | 97 | 0 |
| 30 Sep 23 | 223 | -113 | 90 | 0 |
| 30 Jun 23 | 431 | -7 | 77 | -26 |
| 31 Mar 23 | 373 | -135 | 69 | 0 |
| 31 Dec 22 | 361 | -143 | 58 | 0 |
| 30 Sep 22 | 439 | 73 | 61 | 0 |
| 30 Jun 22 | 304 | -159 | 65 | 52 |
| 31 Mar 22 | 347 | -72 | 64 | 0 |
| 31 Dec 21 | 348 | -73 | 71 | 0 |
| 30 Sep 21 | 121 | -248 | 60 | 0 |
| 30 Jun 21 | 110 | -125 | 56 | 0 |
| 31 Mar 21 | 98 | -91 | 50 | 0 |
| 31 Dec 20 | 110 | -64 | 46 | 0 |
| 30 Sep 20 | 104 | -62 | 46 | 0 |
| 30 Jun 20 | 120 | -25 | 43 | 0 |
| 31 Mar 20 | 127 | -8 | 44 | 0 |
| 31 Dec 19 | 126 | -2 | 43 | 0 |
| 30 Sep 19 | 116 | 4 | 40 | 0 |
| 30 Jun 19 | 109 | 1 | 39 | 0 |
| 31 Mar 19 | 116 | 7 | 38 | 0 |
| 31 Dec 18 | 113 | 3 | 38 | 0 |
| 30 Sep 18 | 107 | -7 | 38 | 0 |
| 30 Jun 18 | 110 | -7 | 38 | 0 |
| 31 Mar 18 | 108 | -8 | 35 | 0 |
| 31 Dec 17 | 105 | -11 | 33 | 0 |
| 30 Sep 17 | 103 | -11 | 33 | 0 |
| 30 Jun 17 | 100 | -14 | 32 | 0 |
| 31 Mar 17 | 102 | -46 | 32 | 0 |
| 31 Dec 16 | 98 | -49 | 31 | 0 |
| 30 Sep 16 | 93 | -63 | 29 | 0 |
| 30 Jun 16 | 96 | -61 | 28 | 0 |
| 31 Mar 16 | 89 | -35 | 27 | 0 |
| 31 Dec 15 | 83 | -21 | 24 | 0 |
| 30 Sep 15 | 74 | -16 | 20 | 0 |
| 30 Jun 15 | 65 | -13 | 17 | 0 |
| 31 Mar 15 | 55 | -9 | 15 | 0 |
| 31 Dec 14 | 42 | -26 | 14 | 0 |
| 30 Sep 14 | 41 | -21 | 13 | 0 |
| 30 Jun 14 | 43 | -28 | 17 | 0 |
| 31 Mar 14 | 41 | -29 | 17 | 0 |
| 31 Dec 13 | 36 | -24 | 15 | 0 |
| 30 Sep 13 | 26 | -22 | 14 | 0 |
| 30 Jun 13 | 13 | -14 | 8 | 0 |
Quality Earnings: VLA is currently unprofitable.
Growing Profit Margin: VLA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VLA is unprofitable, and losses have increased over the past 5 years at a rate of 31.3% per year.
Accelerating Growth: Unable to compare VLA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: VLA has a negative Return on Equity (-79.09%), as it is currently unprofitable.